Ovid Therapeutics (OVID) Cash from Investing Activities (2016 - 2026)

Ovid Therapeutics has reported Cash from Investing Activities for 11 years, with the latest figure at $5.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 16.62% year-over-year to $5.9 million; the trailing twelve-month figure through Mar 2026 stood at -$49.0 million (down 224.04% YoY), and the FY2025 full-year result was -$49.9 million, down 191.32% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $5.9 million, up from -$72.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $30.2 million in Q1 2023, with the low at -$80.7 million in Q2 2022.
• Historically, Cash from Investing Activities has averaged -$4.7 million across 5 years, with a median of $5.1 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 9246.58% — and 2023, when it jumped 2908.96%.
• Ovid Therapeutics' Cash from Investing Activities stood at -$4.2 million in 2022, then tumbled by 1063.59% to -$48.5 million in 2023, then jumped by 143.89% to $21.3 million in 2024, then tumbled by 438.45% to -$72.1 million in 2025, then surged by 108.26% to $5.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $5.9 million (Q1 2026), -$72.1 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.